The epidemiological transition is the transition of diseases from infectious diseases to chronic diseases. Factors leading to these transitions included the introduction of vaccines, increased sanitation, and overall improvements in living standards. All of this has been supported through public health interventions. As a result of transitions, life expectancy has improved not only nationally but also globally. People no longer die from infectious diseases. As a result, they live longer and end up suffering or dying from a chronic disease. An increase in life expectancy therefore led to a change in the conditions from which populations around the world suffered. The immense increase in chronic diseases can therefore be attributed to factors such as public health interventions, lifestyle changes, tobacco use, alcohol consumption and sedentary behaviors [1]. Some of these chronic diseases include, but are not limited to, heart disease, stroke, obesity, and cancer. Many epidemiological researches have concluded that cancer is the second cause of death in the world, after cardiovascular diseases [2]. Stomach cancer, in particular, has been listed not only as the fourth most commonly diagnosed cancer, but also as the second leading cause of cancer-related death worldwide [3,4,5]. Furthermore, most new cases of stomach cancer occurred in developing countries [3,4,5]. In the United States (US), stomach cancer was the leading cause of cancer death until the late 1930s [6,7]. With major improvements since then in initiating stomach cancer, it currently does not stand out among the top ten cancer deaths [6,7]. Rationalization of low ranking, especially in the United States, has been attributed to significant declines in stomach cancer mortality and incidence over...... half of paper...... w.merriam-webster.com /dictionary /seropositive Accessed 23 October 2013.24. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and development of gastric cancer. New England Journal of Medicine. 2001;345:784-89.25. Eva Buiatti E, Palli D, Decarli A, Amadori D, Avellini C, Bianchi S, Biserni R, Cipriani F, Cocco P, Giacosa A, Marubini E, Puntoni R, Vindigni C, Fraumeni Jr. J, Blot W. A Case -Gastric cancer and diet control study in Italy. International Journal of Cancer. 1989;44(4):611-16.26. Parsonnet J, Harris RA, Hack HM, Owens DK. Modeling the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. The Lancet. 1996; 348: 150–54.